The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.

The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.

The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.

Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?

Of the big oncology deals since 2016, there are still plenty that could go either way.

Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.